Ziprasidone attenuates brain injury after focal cerebral ischemia induced by middle cerebral artery occlusion in rats

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 39, Issue 1, 2012, Pages 69-74

  Kam, Kyung Yoon ^a   Jalin, Angela M Anthony ^a   Choi, Yong Won ^a   Kaengkan, Phatcharida ^a   Park, Sung Woo ^a   Kim, Young Hoon ^a   Kang, Sung Goo ^a  

^a Inje University   (South Korea)

Author keywords

Focal cerebral ischemia; Middle cerebral artery occlusion; Neuroprotection; Ziprasidone

Indexed keywords

ZIPRASIDONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; MALE; MICROGLIA; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; RAT; TREATMENT DURATION; TREATMENT RESPONSE;

ANIMALS; ANTIGENS, NUCLEAR; ANTIPSYCHOTIC AGENTS; BIOLOGICAL MARKERS; BRAIN INJURIES; BRAIN ISCHEMIA; CALCIUM-BINDING PROTEINS; CEREBRAL INFARCTION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICROFILAMENT PROTEINS; MICROGLIA; NERVE TISSUE PROTEINS; NEURONS; NEUROPROTECTIVE AGENTS; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; RECOVERY OF FUNCTION; SEVERITY OF ILLNESS INDEX; THIAZOLES;

EID: 84864507020     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.05.010     Document Type: Article

References (53)

1. Abdul-Monim Z., Reynolds G.P., Neill J.C. The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm. Behav Brain Res 2006, 169:263-273.
2. Akpan N., Serrano-Saiz E., Zacharia B.E., Otten M.L., Ducruet A.F., Snipas S.J., et al. Intranasal delivery of caspase-9 inhibitor reduces caspase-6-dependent axon/neuron loss and improves neurological function after stroke. J Neurosci 2011, 31:8894-8904.
3. Bai O., Chlan-Fourney J., Bowen R., Keegan D., Li X.M. Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. J Neurosci Res 2003, 71:127-131.
4. Bai O., Zhang H., Li X.M. Antipsychotic drugs clozapine and olanzapine upregulate bcl-2 mRNA and protein in rat frontal cortex and hippocampus. Brain Res 2004, 1010:81-86.
5. Banasr M., Hery M., Printemps R., Daszuta A. Serotonin-induced increases in adult cell proliferation and neurogenesis are mediated through different and common 5-HT receptor subtypes in the dentate gyrus and the subventricular zone. Neuropsychopharmacology 2004, 29:450-460.
6. Barth V.N., Chernet E., Martin L.J., Need A.B., Rash K.S., Morin M., et al. Comparison of rat dopamine D2 receptor occupancy for a series of antipsychotic drugs measured using radiolabeled or nonlabeled raclopride tracer. Life Sci 2006, 78:3007-3012.
7. Beck S.G., Choi K.C., List T.J. Comparison of 5-hydroxytryptamine1A-mediated hyperpolarization in CA1 and CA3 hippocampal pyramidal cells. J Pharmacol Exp Ther 1992, 263:350-359.
8. Bian Q., Kato T., Monji A., Hashioka S., Mizoguchi Y., Horikawa H., et al. The effect of atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-gamma. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:42-48.
9. Broughton B.R., Reutens D.C., Sobey C.G. Apoptotic mechanisms after cerebral ischemia. Stroke 2009, 40:e331-e339.
10. Chen J., Li Y., Wang L., Zhang Z., Lu D., Lu M., et al. Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. Stroke 2001, 32:1005-1011.
11. Choi D.K., Koppula S., Suk K. Inhibitors of microglial neurotoxicity: focus on natural products. Molecules 2011, 16:1021-1043.
12. Cole S.A., Saleem R., Shea W.P., Sedler M., Sablosky M., Jyringi D., et al. Ziprasidone for agitation or psychosis in dementia: four cases. Int J Psychiatry Med 2005, 35:91-98.
13. Daniel D.G., Copeland L.F. Ziprasidone: comprehensive overview and clinical use of a novel antipsychotic. Expert Opin Investig Drugs 2000, 9:819-828.
14. Danton G.H., Dietrich W.D. Inflammatory mechanisms after ischemia and stroke. J Neuropathol Exp Neurol 2003, 62:127-136.
15. Dirnagl U., Iadecola C., Moskowitz M.A. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 1999, 22:391-397.
16. Frost D.O., Page S.C., Carroll C., Kolb B. Early exposure to haloperidol or olanzapine induces long-term alterations of dendritic form. Synapse 2010, 64:191-199.
17. He J., Kong J., Tan Q.R., Li X.M. Neuroprotective effect of atypical antipsychotics in cognitive and non-cognitive behavioral impairment in animal models. Cell Adh Migr 2009, 3:129-137.
18. Hurtado O., Pradillo J.M., Alonso-Escolano D., Lorenzo P., Sobrino T., Castillo J., et al. Neurorepair versus neuroprotection in stroke. Cerebrovasc Dis 2006, 21(Suppl. 2):54-63.
19. Jha S., Rajendran R., Fernandes K.A., Vaidya V.A. 5-HT2A/2C receptor blockade regulates progenitor cell proliferation in the adult rat hippocampus. Neurosci Lett 2008, 441:210-214.
20. Kamei K., Maeda N., Nomura K., Shibata M., Katsuragi-Ogino R., Koyama M., et al. Synthesis, SAR studies, and evaluation of 1,4-benzoxazepine derivatives as selective 5-HT1A receptor agonists with neuroprotective effect: Discovery of Piclozotan. Bioorg Med Chem 2006, 14:1978-1992.
21. Kato T.A., Monji A., Mizoguchi Y., Hashioka S., Horikawa H., Seki Y., et al. Anti-Inflammatory properties of antipsychotics via microglia modulations: are antipsychotics a 'fire extinguisher' in the brain of schizophrenia?. Mini Rev Med Chem 2011, 11:565-574.
22. Kihara T., Shimohama S., Sawada H., Honda K., Nakamizo T., Kanki R., et al. Protective effect of dopamine D2 agonists in cortical neurons via the phosphatidylinositol 3 kinase cascade. J Neurosci Res 2002, 70:274-282.
23. Kline A.E., Yu J., Horvath E., Marion D.W., Dixon C.E. The selective 5-HT(1A) receptor agonist repinotan HCl attenuates histopathology and spatial learning deficits following traumatic brain injury in rats. Neuroscience 2001, 106:547-555.
24. Klisch J., Bode-Greuel K.M. Ketanserin reduces neuronal calcium accumulation and cell death in the hippocampus of the Mongolian gerbil after transient forebrain ischemia. Brain Res 1992, 578:1-7.
25. Klisch J., Bode-Greuel K.M., Horvath E., Klisch C., Els T. Additive neuroprotective effect of Ketanserin and Ipsapirone on the hippocampal damage after transient forebrain ischemia in the Mongolian gerbil. Neurosci Lett 2003, 342:25-28.
26. Kruyt N.D., Nys G.M., van der Worp H.B., van Zandvoort M.J., Kappelle L.J., Biessels G.J. Hyperglycemia and cognitive outcome after ischemic stroke. J Neurol Sci 2008, 270:141-147.
27. Lakhan S.E., Kirchgessner A., Hofer M. Inflammatory mechanisms in ischemic stroke: therapeutic approaches. J Transl Med 2009, 7:97.
28. Li W.L., Cai H.H., Wang B., Chen L., Zhou Q.G., Luo C.X., et al. Chronic fluoxetine treatment improves ischemia-induced spatial cognitive deficits through increasing hippocampal neurogenesis after stroke. J Neurosci Res 2009, 87:112-122.
29. Lipton P. Ischemic cell death in brain neurons. Physiol Rev 1999, 79:1431-1568.
30. Liu B., Hong J.S. Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J Pharmacol Exp Ther 2003, 304:1-7.
31. Longa E.Z., Weinstein P.R., Carlson S., Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 1989, 20:84-91.
32. Luo C., Xu H., Li X.M. Quetiapine reverses the suppression of hippocampal neurogenesis caused by repeated restraint stress. Brain Res 2005, 1063:32-39.
33. Marco I., Valhondo M., Martin-Fontecha M., Vazquez-Villa H., Del Rio J., Planas A., et al. New Serotonin 5-HT(1A) Receptor Agonists with Neuroprotective Effect against Ischemic Cell Damage. J Med Chem 2011, 54:7986-7999.
34. Matsuyama S., Nei K., Tanaka C. Regulation of glutamate release via NMDA and 5-HT1A receptors in guinea pig dentate gyrus. Brain Res 1996, 728:175-180.
35. Nagasawa H., Kogure K. Correlation between cerebral blood flow and histologic changes in a new rat model of middle cerebral artery occlusion. Stroke 1989, 20:1037-1043.
36. Nemeroff C.B., Lieberman J.A., Weiden P.J., Harvey P.D., Newcomer J.W., Schatzberg A.F., et al. From clinical research to clinical practice: a 4-year review of ziprasidone. CNS Spectr 2005, 10:1-20.
37. Nunn J., Hodges H. Cognitive deficits induced by global cerebral ischaemia: relationship to brain damage and reversal by transplants. Behav Brain Res 1994, 65:1-31.
38. Oksala N.K., Jokinen H., Melkas S., Oksala A., Pohjasvaara T., Hietanen M., et al. Cognitive impairment predicts poststroke death in long-term follow-up. J Neurol Neurosurg Psychiatry 2009, 80:1230-1235.
39. O'Neill M.J., Hicks C.A., Ward M.A., Cardwell G.P., Reymann J.M., Allain H., et al. Dopamine D2 receptor agonists protect against ischaemia-induced hippocampal neurodegeneration in global cerebral ischaemia. Eur J Pharmacol 1998, 352:37-46.
40. Park S.W., Lee C.H., Lee J.G., Lee S.J., Kim N.R., Choi S.M., et al. Differential effects of ziprasidone and haloperidol on immobilization stress-induced mRNA BDNF expression in the hippocampus and neocortex of rats. J Psychiatr Res 2009, 43:274-281.
41. Park S.W., Lee C.H., Lee J.G., Kim L.W., Shin B.S., Lee B.J., et al. Protective effects of atypical antipsychotic drugs against MPP(+)-induced oxidative stress in PC12 cells. Neurosci Res 2011, 69:283-290.
42. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 2005, Elsevier Academic Press, Burlington, MA. 5 ed.
43. Prehn J.H., Backhauss C., Karkoutly C., Nuglisch J., Peruche B., Rossberg C., et al. Neuroprotective properties of 5-HT1A receptor agonists in rodent models of focal and global cerebral ischemia. Eur J Pharmacol 1991, 203:213-222.
44. Rollema H., Lu Y., Schmidt A.W., Sprouse J.S., Zorn S.H. 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol Psychiatry 2000, 48:229-237.
45. Sachs G.S., Ice K.S., Chappell P.B., Schwartz J.H., Gurtovaya O., Vanderburg D.G., et al. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2011, 72:1413-1422.
46. Schmidt A.W., Lebel L.A., Howard H.R., Zorn S.H. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol 2001, 425:197-201.
47. Scott L.K., Green R., McCarthy P.J., Conrad S.A. Agitation and/or aggression after traumatic brain injury in the pediatric population treated with ziprasidone. Clinical article. J Neurosurg Pediatr 2009, 3:484-487.
48. Seeger T.F., Seymour P.A., Schmidt A.W., Zorn S.H., Schulz D.W., Lebel L.A., et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 1995, 275:101-113.
49. Sugino H., Futamura T., Mitsumoto Y., Maeda K., Marunaka Y. Atypical antipsychotics suppress production of proinflammatory cytokines and up-regulate interleukin-10 in lipopolysaccharide-treated mice. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:303-307.
50. Tost H., Braus D.F., Hakimi S., Ruf M., Vollmert C., Hohn F., et al. Acute D2 receptor blockade induces rapid, reversible remodeling in human cortical-striatal circuits. Nat Neurosci 2010, 13:920-922.
51. Yan B., He J., Xu H., Zhang Y., Bi X., Thakur S., et al. Quetiapine attenuates the depressive and anxiolytic-like behavioural changes induced by global cerebral ischemia in mice. Behav Brain Res 2007, 182:36-41.
52. Young C.C., Lujan E. Intravenous ziprasidone for treatment of delirium in the intensive care unit. Anesthesiology 2004, 101:794-795.
53. Yulug B., Yildiz A., Hudaoglu O., Kilic E., Cam E., Schabitz W.R. Olanzapine attenuates brain damage after focal cerebral ischemia in vivo. Brain Res Bull 2006, 71:296-300.